Goldman issues warning on CooperCompanies ahead of earnings
CooperCompanies traded 0.4% higher early on Nasdaq Wednesday at $62.28 after Goldman Sachs lowered its price target to $61 from $69, sticking with a Sell. That values the San Ramon, Calif. medical device company at $12.24 billion. The timing is key. Cooper’s fiscal Q2 results hit in less than two weeks, due June 4 after the bell, with the earnings call scheduled for 5 p.m. ET. There’s not much new company news for investors right now, so the Goldman action puts a pre-earnings flag in the stock.